- Home
- ANAB vs BFST Comparison
ANAB vs BFST Comparison
Compare ANAB & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- BFST
- Stock Information
- Founded
- ANAB 2005
- BFST 2006
- Country
- ANAB United States
- BFST United States
- Employees
- ANAB N/A
- BFST N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- BFST Major Banks
- Sector
- ANAB Health Care
- BFST Finance
- Exchange
- ANAB Nasdaq
- BFST Nasdaq
- Market Cap
- ANAB 759.5M
- BFST 838.4M
- IPO Year
- ANAB 2017
- BFST 2018
- Fundamental
- Price
- ANAB $19.59
- BFST $23.96
- Analyst Decision
- ANAB Buy
- BFST Buy
- Analyst Count
- ANAB 10
- BFST 2
- Target Price
- ANAB $37.75
- BFST $30.00
- AVG Volume (30 Days)
- ANAB 589.1K
- BFST 108.8K
- Earning Date
- ANAB 05-05-2025
- BFST 04-24-2025
- Dividend Yield
- ANAB N/A
- BFST 2.33%
- EPS Growth
- ANAB N/A
- BFST N/A
- EPS
- ANAB N/A
- BFST 2.43
- Revenue
- ANAB $111,872,000.00
- BFST $276,739,000.00
- Revenue This Year
- ANAB N/A
- BFST $26.39
- Revenue Next Year
- ANAB $44.69
- BFST $5.73
- P/E Ratio
- ANAB N/A
- BFST $9.85
- Revenue Growth
- ANAB 387.20
- BFST 11.75
- 52 Week Low
- ANAB $12.21
- BFST $18.97
- 52 Week High
- ANAB $41.31
- BFST $30.30
- Technical
- Relative Strength Index (RSI)
- ANAB 48.98
- BFST 55.87
- Support Level
- ANAB $18.51
- BFST $23.20
- Resistance Level
- ANAB $21.52
- BFST $24.03
- Average True Range (ATR)
- ANAB 1.16
- BFST 0.64
- MACD
- ANAB -0.26
- BFST 0.18
- Stochastic Oscillator
- ANAB 26.97
- BFST 87.69
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.